A new study highlights growing concerns that the increasing dominance of private equity in India's healthcare sector is shifting institutional priorities toward shareholder returns, potentially at the expense of patient care and affordability.
The research suggests that the influx of global financial capital is making regulatory oversight more difficult, as decision-making becomes increasingly centered on financial performance rather than clinical outcomes.
The findings come as healthcare stocks have emerged as a safe haven for investors rotating out of technology equities.
Recent market data indicates a notable comeback for the healthcare sector, with pharmaceutical and biotech equities attracting renewed investor interest.
This capital rotation reflects a broader shift in market sentiment, as funds move away from high-growth tech names into more defensive healthcare plays.
However, the structural changes driven by private equity ownership present a complex challenge for regulators and policymakers.